| pubmed-article:1651681 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1651681 | lifeskim:mentions | umls-concept:C0003392 | lld:lifeskim |
| pubmed-article:1651681 | lifeskim:mentions | umls-concept:C0024660 | lld:lifeskim |
| pubmed-article:1651681 | lifeskim:mentions | umls-concept:C1336767 | lld:lifeskim |
| pubmed-article:1651681 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:1651681 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:1651681 | pubmed:dateCreated | 1991-9-16 | lld:pubmed |
| pubmed-article:1651681 | pubmed:abstractText | Topoisomerase II is now viewed as an important cellular target of antitumor drugs including both DNA intercalators (m-AMSA, ellipticine and Adriamycin) and the nonintercalator epipodophyllotoxin derivatives (VP-16 and VM-26). Topoisomerase I is also shown to be the cellular target of camptotecin. These drugs targeting topoisomerase have been used to establish a relationship between drug-induced cleavable complex formation and cytotoxicity. Mechanistically oriented screening based on the identification of these chemotherapeutic targets have identified a number of antitumor agents that induce topoisomerases mediated DNA cleavage. The new antitumor drugs targeting topoisomerases are reviewed. | lld:pubmed |
| pubmed-article:1651681 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:1651681 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1651681 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1651681 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1651681 | pubmed:issn | 0385-0684 | lld:pubmed |
| pubmed-article:1651681 | pubmed:author | pubmed-author:NakanoHH | lld:pubmed |
| pubmed-article:1651681 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1651681 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:1651681 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1651681 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1651681 | pubmed:pagination | 1550-5 | lld:pubmed |
| pubmed-article:1651681 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:meshHeading | pubmed-meshheading:1651681-... | lld:pubmed |
| pubmed-article:1651681 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1651681 | pubmed:articleTitle | [Antitumor agents targeting mammalian topoisomerases]. | lld:pubmed |
| pubmed-article:1651681 | pubmed:affiliation | Tokyo Research Laboratories, Kyowa Hakko Co. Ltd., Japan. | lld:pubmed |
| pubmed-article:1651681 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1651681 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:1651681 | pubmed:publicationType | Review | lld:pubmed |
